MX2009006007A - Profarmacos y metodos para hacer y usar los mismos. - Google Patents
Profarmacos y metodos para hacer y usar los mismos.Info
- Publication number
- MX2009006007A MX2009006007A MX2009006007A MX2009006007A MX2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrugs
- methods
- parent drug
- making
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87351906P | 2006-12-05 | 2006-12-05 | |
| PCT/US2007/024984 WO2008070149A2 (en) | 2006-12-05 | 2007-12-05 | Prodrugs and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006007A true MX2009006007A (es) | 2009-07-17 |
Family
ID=39361296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006007A MX2009006007A (es) | 2006-12-05 | 2007-12-05 | Profarmacos y metodos para hacer y usar los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080318905A1 (https=) |
| EP (1) | EP2121029A2 (https=) |
| JP (1) | JP2010511717A (https=) |
| KR (1) | KR20090086627A (https=) |
| CN (1) | CN101678120A (https=) |
| AU (1) | AU2007328007A1 (https=) |
| BR (1) | BRPI0719937A2 (https=) |
| CA (1) | CA2671737A1 (https=) |
| MX (1) | MX2009006007A (https=) |
| NO (1) | NO20092527L (https=) |
| RU (1) | RU2009125597A (https=) |
| WO (1) | WO2008070149A2 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| JP5221514B2 (ja) * | 2007-03-06 | 2013-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物及びその製造方法 |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| RU2010151953A (ru) | 2008-05-20 | 2012-06-27 | Ньюроджесэкс, Инк. (Us) | Карбонатные продукты и способы их применения |
| KR101717145B1 (ko) | 2008-05-20 | 2017-03-16 | 노이로제스엑스, 인코포레이티드 | 간보호제 아세트아미노펜 공통 프로드러그 |
| KR101698028B1 (ko) | 2008-05-20 | 2017-01-26 | 노이로제스엑스, 인코포레이티드 | 수용성 아세트아미노펜 유사체 |
| EP2307375B1 (en) | 2008-07-28 | 2014-11-19 | Pfizer Inc. | Phenanthrenone compounds, compositions and methods |
| WO2010033540A1 (en) * | 2008-09-19 | 2010-03-25 | Mallinckrodt Inc. | Crystalline forms of fentanyl alkaloid |
| LT2445502T (lt) | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
| CA2937222C (en) | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| BR112013023847B1 (pt) | 2011-03-18 | 2021-02-23 | Alkermes Pharma Ireland Limited | composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas |
| ES2883259T3 (es) * | 2011-07-28 | 2021-12-07 | Kempharm Inc | Profármacos de metilfenidato, procesos para la obtención y uso de los mismos |
| AU2012312136B2 (en) | 2011-09-22 | 2017-06-29 | Acorda Therapeutics, Inc. | Acetaminophen conjugates, compositions and methods of use thereof |
| NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
| AU2013235523B9 (en) | 2012-03-19 | 2018-01-04 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| AU2013235526B2 (en) | 2012-03-19 | 2017-11-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| WO2014172482A1 (en) | 2013-04-17 | 2014-10-23 | Robert Alfred Volkmann | Compounds for treatment of pain |
| WO2014172478A1 (en) | 2013-04-17 | 2014-10-23 | VOLKMANN Robert | Compounds for treatment of pain |
| EP3004115B1 (en) | 2013-05-24 | 2019-03-06 | Rhodes Technologies | Opioid ketal compounds and uses thereof |
| WO2015082932A1 (en) | 2013-12-05 | 2015-06-11 | The University Of Bath | Novel opioid compounds and their uses |
| CN106132415A (zh) | 2014-03-20 | 2016-11-16 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| EP3294278B1 (en) | 2015-05-13 | 2022-05-11 | 4P-Pharma | Apomorphine for the treatment of methylphenidate induced hyperactivity |
| US20170273974A1 (en) * | 2016-03-24 | 2017-09-28 | Medrx Co., Ltd | Patch preparations with misuse prevention features |
| EP3703694A4 (en) * | 2017-11-03 | 2021-08-18 | Nirsum Laboratories, Inc. | MEDICINES ANTAGONISTS OF OPIOID RECEPTORS |
| EP3755704A1 (en) | 2018-02-23 | 2020-12-30 | Rhodes Technologies Inc. | Novel opioid compounds and uses thereof |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
| US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
| US12030868B2 (en) | 2018-10-13 | 2024-07-09 | Pfizer Ireland Pharmaceuticals | Prodrugs of CGRP antagonists |
| US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
| CN114072403A (zh) * | 2019-05-07 | 2022-02-18 | 百时美施贵宝公司 | 前药化合物 |
| FI130262B (en) * | 2019-08-30 | 2023-05-17 | Medicortex Finland Oy | Formulations and compositions for use in the prevention or treatment of brain injury and neurodegenerative diseases |
| KR20220071223A (ko) * | 2019-09-30 | 2022-05-31 | 닛뽕 케미파 가부시키가이샤 | 아제판 유도체 |
| CN114380859B (zh) * | 2020-10-22 | 2024-11-01 | 威智医药股份有限公司 | 磷酸二苄酯及焦磷酸四苄酯的制备方法 |
| CN117805249A (zh) * | 2022-09-23 | 2024-04-02 | 合肥瀚微生物科技有限公司 | 一种抑郁症诊断的生物标记物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
| EP1041987B1 (en) * | 1997-12-22 | 2006-04-19 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone |
| KR20010033811A (ko) * | 1997-12-31 | 2001-04-25 | 토마스 안 빅토리아 | 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법 |
| US6703398B2 (en) * | 2001-11-26 | 2004-03-09 | Oliver Yoa-Pu Hu | Orally administered analgesic compositions containing nalbuphine |
| JP2006520392A (ja) * | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法 |
| PT1765292T (pt) * | 2004-06-12 | 2017-12-29 | Collegium Pharmaceutical Inc | Formulações de fármacos dissuasoras de abuso |
-
2007
- 2007-12-05 CN CN200780050871A patent/CN101678120A/zh active Pending
- 2007-12-05 EP EP07862579A patent/EP2121029A2/en not_active Withdrawn
- 2007-12-05 BR BRPI0719937-6A2A patent/BRPI0719937A2/pt not_active IP Right Cessation
- 2007-12-05 AU AU2007328007A patent/AU2007328007A1/en not_active Abandoned
- 2007-12-05 JP JP2009540292A patent/JP2010511717A/ja active Pending
- 2007-12-05 MX MX2009006007A patent/MX2009006007A/es not_active Application Discontinuation
- 2007-12-05 KR KR1020097013918A patent/KR20090086627A/ko not_active Withdrawn
- 2007-12-05 US US11/999,660 patent/US20080318905A1/en not_active Abandoned
- 2007-12-05 CA CA002671737A patent/CA2671737A1/en not_active Abandoned
- 2007-12-05 RU RU2009125597/04A patent/RU2009125597A/ru not_active Application Discontinuation
- 2007-12-05 WO PCT/US2007/024984 patent/WO2008070149A2/en not_active Ceased
-
2009
- 2009-07-03 NO NO20092527A patent/NO20092527L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008070149A3 (en) | 2009-12-10 |
| AU2007328007A1 (en) | 2008-06-12 |
| US20080318905A1 (en) | 2008-12-25 |
| KR20090086627A (ko) | 2009-08-13 |
| JP2010511717A (ja) | 2010-04-15 |
| NO20092527L (no) | 2009-09-04 |
| EP2121029A2 (en) | 2009-11-25 |
| WO2008070149A2 (en) | 2008-06-12 |
| RU2009125597A (ru) | 2011-01-20 |
| BRPI0719937A2 (pt) | 2014-03-11 |
| CN101678120A (zh) | 2010-03-24 |
| CA2671737A1 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006007A (es) | Profarmacos y metodos para hacer y usar los mismos. | |
| WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
| BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
| PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
| WO2008157103A3 (en) | Modified release solid or semi-solid dosage forms | |
| EP2562177A3 (en) | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof | |
| SG166093A1 (en) | Inhibitors of brutonæs tyrosine kinase | |
| MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
| TW200621730A (en) | Chemical compounds | |
| WO2008070346A3 (en) | Methods for treating pain with reduced nuasea and vomiting | |
| WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
| WO2008064192A3 (en) | Modified release analgesic suspensions | |
| GB2423928A (en) | Methods and compositions for treating pain | |
| WO2008085765A3 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| EP2061456A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME | |
| MX2012007225A (es) | Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d. | |
| MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| GB2446341A (en) | Method and system for transdermal drug delivery | |
| WO2009045053A3 (en) | A cancer sensitizer comprising chlorogenic acid | |
| WO2008041116A3 (en) | Formulations of active principles incorporated in slns suitable for transdermal administration | |
| WO2006133194A3 (en) | Methods for treating viral infection with oral or injectible drug solution | |
| EA201270551A1 (ru) | Лечение нейротоксичности, ассоциированной с комбинациями 5-fu или его пролекарств с ингибиторами dpd | |
| IL197769A (en) | The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |